Laboratorio Farmaceutico SIT (hereinafter “SIT”) announces the acquisition of the pharmaceutical product “DINTOINA”.
DINTOINA is a reference product for the treatment of generalized epilepsy, excluding petit mal and partial seizures.
In addition to its neurological applications, DINTOINA is also used in the treatment of other conditions, confirming its proven effectiveness across multiple therapeutic areas.
This acquisition marks a significant step in SIT’s growth strategy in the Central Nervous System (CNS) field and expands the pharmaceutical company’s portfolio.
With a presence in over 70 countries, and a pipeline of more than 75 branded pharmaceutical products, in addition to Medical Devices and Food Supplements, SIT continues its path of innovation and development, strengthening its offering to meet the needs of patients and healthcare professionals with reliable, high-quality solutions.
The law firm De Berti Jacchia assisted SIT throughout all phases of the transaction, from structuring the agreement to its finalization, with a dedicated team led by Partner Pietro Meda, supported by Associate Francesca Zironi. Intellectual property matters were handled by Partner Andrea Terragni and Associate Laura Bussoli.